Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

C3 glomerulopathy.

H Terence Cook1

  • 1Department of Medicine, Imperial College London, Hammersmith, London, UK.

F1000Research
|March 31, 2017
PubMed
Summary
This summary is machine-generated.

C3 glomerulopathy is a kidney disease from abnormal complement activation, depositing C3 in glomeruli. Understanding its unique cause improves diagnosis and may lead to new therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complement inhibitors and B cell-modifying agents for IgA nephropathy-a Kidney Disease: Improving Global Outcomes (KDIGO) commentary.

Kidney international·2026
Same author

Characterizing the NIH Activity and Chronicity Indices in 2 Independent Lupus Nephritis Cohorts.

Kidney international reports·2026
Same author

Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

Kidney international·2025
Same author

KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).

Kidney international·2025
Same author

Kidney Complement Immunohistochemistry in Thrombotic Microangiopathy Subtypes.

Kidney international reports·2025
Same journal

Sentiment Analysis of Acceptance TVET Online Courses on the Skill Academy App from Google Play: Leveraging Text Mining with Comparison Machine Learning Model.

F1000Research·2026
Same journal

Emotional intelligence: An important skill to learn now more than ever.

F1000Research·2026
Same journal

East Mediterranean Lineage of <i>Brucella melitensis</i> in Human Isolates and Milk Samples in Oman Using MLVA-14.

F1000Research·2026
Same journal

Application of K-Means Clustering for Job Applicant Analysis in Construction Firms Using R.

F1000Research·2026
Same journal

The influence of self-esteem and emotional intelligence on addiction to social networks in Peruvian university students.

F1000Research·2026
Same journal

A Bibliometric Analysis of Music's Role in Promoting Well-Being in Health Science Research.

F1000Research·2026
See all related articles

Area of Science:

  • Nephrology
  • Immunology
  • Complement System Biology

Background:

  • C3 glomerulopathy is a kidney disease characterized by complement component C3 deposition in glomeruli.
  • Previously classified by morphology, its unique pathogenesis involving complement dysregulation is now recognized.
  • It represents approximately 1% of all renal biopsies.

Purpose of the Study:

  • To define C3 glomerulopathy as a distinct clinical entity.
  • To elucidate the role of complement dysregulation in its pathogenesis.
  • To provide a foundation for understanding its clinical course and developing targeted therapies.

Main Methods:

  • Review of existing literature and case studies defining C3 glomerulopathy.
  • Analysis of pathological findings, particularly C3 deposition in glomeruli.
Keywords:
C3 complementglomerular inflammationrenal pathology

Related Experiment Videos

  • Examination of complement pathway activation markers.

    • Main Results:

    • C3 glomerulopathy is characterized by isolated C3 deposition in glomeruli, independent of C1q or IgG.
    • Abnormal complement regulation, particularly of the alternative pathway, is the underlying cause.
    • Variable glomerular inflammation and damage are observed.

    Conclusions:

    • The clear definition of C3 glomerulopathy has improved understanding of its pathogenesis.
    • This understanding is crucial for accurate diagnosis and classification of these kidney diseases.
    • Future research will likely focus on developing specific therapies targeting complement dysregulation.